News

A 2013 study in the International Journal of Cardiology found that the bergamot polyphenolic extract, when taken with the popular cholesterol-lowering rosuvastatin, enhanced the potency of the statin

The NDA is based on the results of two Phase III clinical trials that met their primary endpoints. The 12-week efficacy portion of the trials showed significant superiority

Ozurdex is approved for treatment of DME patients who are pseudophakic (have an artificial lens implant), or who are considered insufficiently responsive to, or unsuitable for non-corticosteroids therapy.

By using the new technology, doctors will be able to quickly diagnose the virus. Professor Jiro Yasuda was quoted by AFP as saying that the new method is

If approved, Nuplazid will establish a new and distinctly different pharmacological approach to treat psychosis. The company has already completed a pivotal Phase III trial of Nuplazid in

The COMET-1 trial evaluated cabozantinib in mCRPC patients whose disease progressed after treatment with docetaxel as well as abiraterone and/or enzalutamide. The trial failed to meet its primary

NB32 is a fixed-dose combination of naltrexone sustained release (SR) and bupropion SR. U.S. Patent No. 8,815,889 claims methods for treating insulin resistance using a composition including naltrexone

APD811 is an investigational drug candidate internally discovered and developed by Arena for the treatment of vasospastic diseases, such as PAH. Arena Operations Global Regulatory Affairs senior vice-president

Motolimod is indicated for ovarian cancer patients whose disease has progressed on or recurred after platinum-based chemotherapy. The new Toll-like receptor 8 (TLR8) immunotherapy, motolimid is currently being